Early generation EGFR TKIs, such as gefitinib and erlotinib, upregulated the protein level of SQSTM1 in a dose- and time-dependent manner in three NSCLC cells with different genetic backgrounds, A549 (wild-type EGFR), HCC827 (exon 19 deletion in EGFR), and NCI-H460 cells (H460, wild-type EGFR) (Fig. 1a, b, Supplemental Fig. 1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.